March 16 (Reuters) - Pfizer Inc:

* PFIZER- PHASE 3 STUDY SHOWS XTANDI® (ENZALUTAMIDE) PLUS LEUPROLIDE IMPROVES METASTASIS-FREE SURVIVAL IN MEN WITH NON-METASTATIC PROSTATE CANCER

* PFIZER - STUDY MET PRIMARY ENDPOINT WITH STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN METASTASIS-FREE SURVIVAL FOR PATIENTS TREATED WITH XTANDI PLUS LEUPROLIDE VERSUS PLACEBO PLUS LEUPROLIDE

* A POSITIVE TREND IN THE KEY SECONDARY ENDPOINT OF OVERALL SURVIVAL (OS) WAS ALSO OBSERVED, BUT THESE DATA WERE NOT YET MATURE Source text: https://bit.ly/3FrcY4o Further company coverage: